Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
ALZN is expected to report earnings to fall 97.94% to -5 cents per share on January 03
Q4'23
Est.
$-0.05
Q2'25
Missed
by $1.84
Q1'25
Beat
by $0.41
Q3'23
Missed
by $0.56
Q2'23
Missed
by $0.42
The last earnings report on July 22 showed earnings per share of -243 cents, missing the estimate of -58 cents. With 249.60K shares outstanding, the current market capitalization sits at 2.37M.